Find a Physician | How to Contribute | About Us | Clinical Trials
Select a Cancer Type:
Call 312-695-1102 with questions about Clinical Trials
Clinical Trials

Clinical Trial DRUG 010

A Phase II/III Randomized Trial of Two Doses of MK-3475 (SCH900475) versus Docetaxel in Previously Treated Subjects with Non-Small Cell Lung Cancer
Principal Investigator
Jyoti Patel
  • Status: CLOSED
  • Study Type: Therapeutic, Treatment
  • Protocol No:.DRUG 010
The purpose of this study is to test the safety and tolerability of the research study drug, MK-3475, and to test how effective it is compared to the standard of care, docetaxel, for non-small cell lung cancer.
This is a research study to test MK-3475, a drug that has not been approved by the United States Food and Drug Administration (FDA) for sale in this country. Docetaxel is FDA approved for sale in the United States and other countries and may be available by prescription for patients with non-small cell lung cancer.
Some of the eligibility criteria include:
  • Participants must have non-small cell lung cancer that has progressed (gotten worse) after prior treatment on a platinum-based chemotherapy regimen.
  • Participants must be 18 or older.
Note: This is only a partial list of eligibility criteria. Please contact the Lurie Cancer Center for complete screening information if you are interested in this clinical trial.
Description of Treatment
Participants in this study will be assigned by chance to get either the study drug, MK-3475 or docetaxel. Both drugs are given through the vein (IV) every 3 weeks.
Sara Duffey
Clinical Research and Education Specialist
Robert H. Lurie Comprehensive Cancer Center

Find Related Clinical Trials

Browse by Disease Sites

Other Clinical Trials by Jyoti Patel

last updated: 25-Nov-15 06:17 PM


Clinical trial availability changes frequently. Please check this site often for updates or call 312.695.1102 for personal assistance.